- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02607631
A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor
July 7, 2020 updated by: Myung-Ju Ahn, Samsung Medical Center
A Phase II Study of Pembrolizumab for Patients With Thymic Epithelial Tumor Who Progressed After at Least One Previous Regimen of Cisplatin-Containing Chemotherapy
This is a Phase II single center, open-label, single arm study in patients with advanced thymic epithelial tumors after failure of cisplatin-based combination chemotherapy.
Patients will be treated with Pembrolizumab 200 mg every 3 weeks.
Study Overview
Study Type
Interventional
Enrollment (Actual)
33
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Be willing and able to provide written informed consent/assent for the trial.
- Be 18 years of age on day of signing informed consent.
- Histologically proven thymic epithelial tumor (TET) patients
- Inoperable or metastatic disease
- More than one previous chemotherapy including at least one platinum-based regimen
- At least one measurable lesion based on RECIST 1.1
- Patients who could submit at least one unstained slide to evaluate the PD-L1 expression status (PD-L1 status, which is positive (expression > 1percent of tumor cells) or negative, is the prerequiste for the enrollment. If the submitted slides are unacceptable for the analysis for PD-L1 and there is no remained slide, the patient cannot be enrolled)
- Have a performance status of 0 or 2 on the ECOG Performance Scale.
- Demonstrate adequate organ function as defined in Table 1. Laboratory test must be performed within 10 days before date of treatment.
- Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
- Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.
Exclusion Criteria:
- Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment.
- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
- Has an active automimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjorgen's syndrome will not be excluded from the study.
- Has evidence of interstitial lung disease or active, non-infectious pneumonitis.
- Has an active infection requiring systemic therapy.
- Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
- Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
- Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
- Has received a live vaccine within 30 days prior to the first dose of trial treatment.
- Uncontrolled systemic illness such as DM, CHF, unstable angina, hypertension or arrhythmia
- Has known active tuberculosis which was not treated
- Has a known history of hypersensitivity to pemborolizumab
- Has a treatment history wih mAb within 4 weeks prior to the first dose of trial treatment
- Has had radiotherapy or chemotherapy within 14 days of the first does of trial treatment. Subjects who received radiotherapy >14 days prior to randomization must have completely recovered from any therapy related AEs/toxicities except peripheral neuropathy less than grade II
- Has a known history of psychosis or substance abuse
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single arm
Pembrolizumab 200mg IV every 3 weeks until tumor progression or unacceptable toxicity
|
treated with Pembrolizumab 200 mg every 3 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response rate by RECIST 1.1
Time Frame: 24 months
|
complete response plus partial response as determined by RECIST 1.1
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: 24 months
|
include safety profiles
|
24 months
|
Progression free survival
Time Frame: 24 months
|
time from the on-study date to date of disease progression
|
24 months
|
Overall survival
Time Frame: 24 months
|
time from the on-study date to death as a result of any cause
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Myung-Ju Ahn, Prof., Samsung Medical Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2015
Primary Completion (Actual)
February 1, 2018
Study Completion (Actual)
August 1, 2018
Study Registration Dates
First Submitted
October 7, 2015
First Submitted That Met QC Criteria
November 17, 2015
First Posted (Estimate)
November 18, 2015
Study Record Updates
Last Update Posted (Actual)
July 9, 2020
Last Update Submitted That Met QC Criteria
July 7, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015-04-132-005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thymic Epithelial Tumors
-
National Cancer Institute (NCI)CompletedThymic Carcinoma | Thymoma | Thymic Carcinoid | Thymic Neuroendocrine TumorsUnited States
-
Shanghai Chest HospitalRecruitingThymic Carcinoma | Thymic Epithelial Tumor | Thymic CancerChina
-
Erasmus Medical CenterHospices Civils de Lyon; Maastro Clinic, The NetherlandsRecruitingThymic Carcinoma | Thymoma | Thymic Epithelial Tumor | Thymoma and Thymic CarcinomaNetherlands
-
Morten Mau-SoerensenHospices Civils de Lyon; Gustave Roussy, Cancer Campus, Grand Paris; Institut... and other collaboratorsUnknownThymoma | Advanced Thymic Epithelial TumourDenmark, France
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingUnresectable Thymic Carcinoma | Metastatic Thymic Carcinoma | Locally Advanced Thymic Carcinoma | Recurrent Thymic CarcinomaUnited States
-
Institut CurieRecruiting
-
Georgetown UniversityHackensack Meridian Health; Karyopharm Therapeutics IncTerminatedThymoma | Advanced Thymic Epithelial TumorUnited States
-
National Cancer Institute (NCI)RecruitingSmall Cell Lung Cancer | Non-Small Cell Lung Cancer | Extrapulmonary Small Cell Cancer | Pulmonary Neuroendocrine Tumors | Thymic Epithelial TumorsUnited States
-
Fudan UniversityCompletedThymoma and Thymic CarcinomaChina
-
Fudan UniversityRecruitingThymoma and Thymic CarcinomaChina
Clinical Trials on Pembrolizumab
-
University Medical Center GroningenCompleted
-
Incyte CorporationMerck Sharp & Dohme LLCCompletedMelanomaUnited States, France, Italy, United Kingdom, Spain, Belgium, Israel, Mexico, Japan, Canada, Netherlands, Sweden, Korea, Republic of, Australia, Russian Federation, Chile, Germany, Poland, Ireland, New Zealand, Denmark, Switzerland, South Africa
-
Merck Sharp & Dohme LLCCompletedMelanomaAustralia, South Africa, Spain, Sweden
-
Acerta Pharma BVMerck Sharp & Dohme LLCCompletedMetastatic Urothelial CarcinomaUnited States
-
HUYABIO International, LLC.Active, not recruitingNon Small Cell Lung CancerUnited States
-
Prof. Dr. Matthias PreusserUnknownPrimary Central Nervous System LymphomaAustria
-
Yonsei UniversityNot yet recruitingMucosal Melanoma | Acral MelanomaKorea, Republic of
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Merck Sharp & Dohme LLC; PTC TherapeuticsRecruitingColorectal Cancer | Endometrium CancerNetherlands
-
Michael BoyiadzisMerck Sharp & Dohme LLCCompletedAcute Myeloid LeukemiaUnited States